Abstract
Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.
Keywords: Endocrine therapy, Endocrine resistance, Estrogen receptor, HER2, AIs, SERMs, SERDs
Anti-Cancer Agents in Medicinal Chemistry
Title:Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Volume: 13 Issue: 3
Author(s): Jinjia Chang and Weimin Fan
Affiliation:
Keywords: Endocrine therapy, Endocrine resistance, Estrogen receptor, HER2, AIs, SERMs, SERDs
Abstract: Endocrine therapy has developed rapidly and become most effective and clearly target form of adjuvant therapy for hormone sensitive breast cancer. Adjuvant endocrine therapy for breast cancer can be given after surgery or radiotherapy, and also prior, or subsequent to chemotherapy. Current commonly used drugs for adjuvant endocrine therapy can be divided into following three classes: selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and selective estrogen receptor down-regulators (SERDs). Unfortunately, tumor cells may develop resistance to endocrine therapy, which become a major obstacle limiting the success of breast cancer treatment. The complicated crosstalk, both genomic and nongenomic, between estrogen receptor and growth factors was considered to be a crucial factor contributing to endocrine resistance. However, the progression of resistance to endocrine therapy supposes to be a progressive, step-wise procedure and the underlying mechanism remains unclear. In this review, we would summarize the possible biology and molecular mechanisms that underlie endocrine resistance, and also some novel strategies to overcoming this issue.
Export Options
About this article
Cite this article as:
Chang Jinjia and Fan Weimin, Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1871520611313030009
DOI https://dx.doi.org/10.2174/1871520611313030009 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Opto-Acoustic Imaging of Drug Discovery Biomarkers
Current Pharmaceutical Biotechnology SOX4 Serves an Oncogenic Role in the Tumourigenesis of Human Breast Adenocarcinoma by Promoting Cell Proliferation, Migration and Inhibiting Apoptosis
Recent Patents on Anti-Cancer Drug Discovery In-Vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models
Letters in Drug Design & Discovery Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals The Role of NF-κB Inhibitors in Cell Response to Radiation
Current Medicinal Chemistry Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer
Current Cancer Drug Targets Selective Estrogen Receptor Modulators (SERMs): Effects on Multiple Organ Systems
Current Medicinal Chemistry Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments
Current Drug Metabolism Phosphorylation Processes Controlling Aromatase Activity in Br east Cancer: An Update
Mini-Reviews in Medicinal Chemistry Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter
Current Drug Metabolism Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
Current Medicinal Chemistry Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Serum of Blood Separation by Means of Dynamic Electrochromatography in a Centrifugal and Electromagnetic Gradient
Recent Patents on Biotechnology Microfluidic-Based Platform for the Evaluation of Nanomaterial-Mediated Drug Delivery: From High-Throughput Screening to Dynamic Monitoring
Current Pharmaceutical Design